Veda Giri, MD
Professor of Internal Medicine (Medical Oncology)Cards
Appointments
Additional Titles
Division Chief, Clinical Cancer Genetics
Director, Cancer Genetics and Prevention Program
Director, Early Onset Cancer Program
Contact Info
Yale School of Medicine
333 Cedar Street WWW214A
New Haven, CONNECTICUT 06520
United States
Appointments
Additional Titles
Division Chief, Clinical Cancer Genetics
Director, Cancer Genetics and Prevention Program
Director, Early Onset Cancer Program
Contact Info
Yale School of Medicine
333 Cedar Street WWW214A
New Haven, CONNECTICUT 06520
United States
Appointments
Additional Titles
Division Chief, Clinical Cancer Genetics
Director, Cancer Genetics and Prevention Program
Director, Early Onset Cancer Program
Contact Info
Yale School of Medicine
333 Cedar Street WWW214A
New Haven, CONNECTICUT 06520
United States
About
Titles
Professor of Internal Medicine (Medical Oncology)
Division Chief, Clinical Cancer Genetics; Director, Cancer Genetics and Prevention Program; Director, Early Onset Cancer Program
Biography
Veda N. Giri, MD is a medical oncologist with specialization in clinical cancer genetics. Dr. Giri is Division Chief of Clinical Cancer Genetics for Yale Cancer Center and Smilow Cancer Hospital and Assistant Director of Clinical Cancer Genetics for Yale Cancer Center, where she leads an integrated and comprehensive effort in cancer genetic evaluation to inform precision medicine, tailored cancer screening, and hereditary cancer risk. She is also Director of the Early Onset Cancer Program. In 2023 she was named a Fellow of the American Society of Clinical Oncology (FASCO).
Dr. Giri's research portfolio includes population science studies focused on genetic evaluation of cancer risk, disparities in access to genetic testing and genetic counseling, and implementation research. She has led numerous studies to advance the field of genetic counseling and genetic testing for inherited prostate cancer. Dr. Giri started the first Men’s Genetic Risk Clinic in the US in 2014 focused on genetic evaluation of inherited prostate cancer in the setting of multidisciplinary care. Dr. Giri also co-chaired the 2017 and 2019 Philadelphia Prostate Cancer Consensus Conferences that addressed development of comprehensive frameworks for genetic evaluation and implementation of genetic testing for prostate cancer. She is the Principal Investigator of multiple grant-funded prostate cancer genetic evaluation studies spanning genetic counseling, genetic testing, disparities, behavioral science, and implementation research. As leader of clinical cancer genetics, Dr. Giri plans to expand population science studies across cancer populations and in the community setting.
Dr. Giri received her medical degree from Sidney Kimmel Medical College (previously Jefferson Medical College) and proceeded to complete her residency in Internal Medicine and fellowship in Hematology-Oncology at the University of Michigan. She then completed advanced training in molecular cancer genetics and cancer risk assessment at Fox Chase Cancer Center. She also has a certification in cancer risk assessment from City of Hope Comprehensive Cancer Center. Dr. Giri currently serves on several national committees including the NIH PDQ® Cancer Genetics Editorial Board, ASCO Evidence-Based Medicine Committee, ASCO Cancer Care Delivery Council, ASCO Health Equity and Outcomes Committee, and ASCO Coverage and Reimbursement Steering Committee contributing expertise in cancer risk assessment and genetics at the national level.
Appointments
Medical Oncology
ProfessorPrimary
Other Departments & Organizations
Education & Training
- MD
- Sidney Kimmel Medical College, Thomas Jefferson University
- BS
- Pennsylvania State University-Six-year premedical-medical program, BS, Science (1993)
Research
Overview
Dr. Giri's research portfolio includes population science studies focused on genetic evaluation of cancer risk, disparities in access to genetic testing and genetic counseling, and implementation research. She has led numerous studies to advance the field of genetic counseling and genetic testing for inherited prostate cancer.
Medical Subject Headings (MeSH)
ORCID
0000-0002-7268-5913
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Sakinah Carter Suttiratana, PhD, MPH, MBA
Publications
Featured Publications
Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention
Seibert T, Garraway I, Plym A, Mahal B, Giri V, Jacobs M, Cheng H, Loeb S, Helfand B, Eeles R, Morgan T. Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention. European Urology 2023, 83: 241-248. PMID: 36609003, DOI: 10.1016/j.eururo.2022.12.021.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricMeSH Keywords and ConceptsConceptsTimes higher riskGenetic risk scoreHigh genetic risk scoreLethal prostate cancerProstate cancerHigh genetic riskHigh riskRare pathogenic mutationsHealthy lifestyleEarly detectionPCa riskRisk predictionHigh-grade prostate cancerGenetic riskAggressive prostate cancerProstate cancer riskGenetic risk assessmentDNA damage repair genesGenetic risk predictionPCa mortalityAggressive diseaseLeading causeFamily historyCancer riskElevated risk
2024
Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing
Leader A, Rebbeck T, Oh W, Patel A, Winer E, Bailey L, Gomella L, Lumpkins C, Garraway I, Aiello L, Baskin M, Cheng H, Cooney K, Ganzak A, George D, Halabi S, Hathaway F, Healy C, Kim J, Leapman M, Loeb S, Maxwell K, McNair C, Morgan T, Prindeville B, Soule H, Steward W, Suttiratana S, Taplin M, Yamoah K, Fortune T, Bennett K, Blanding-Godbolt J, Gross L, Giri V. Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing. BMC Public Health 2024, 24: 2533. PMID: 39289635, PMCID: PMC11409532, DOI: 10.1186/s12889-024-20008-8.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsSocioecological modelGermline testingHealthcare institutionsCancer genetic testingHereditary cancer implicationsEquity frameworkBlack malesCancer screeningReduce disparitiesBackgroundBlack menCommunity liaisonCommunity stakeholdersMixed-methods approachOvercome barriersImprovement PartnershipCommunity eventsCascade testingModified Delphi modelRate of prostate cancerGenetic testingCancer implicationsEducation programsBlack menEquitable strategiesIncreased engagementBRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients
Cheng H, Shevach J, Castro E, Couch F, Domchek S, Eeles R, Giri V, Hall M, King M, Lin D, Loeb S, Morgan T, Offit K, Pritchard C, Schaeffer E, Szymaniak B, Vassy J, Katona B, Maxwell K. BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients. JAMA Oncology 2024, 10: 1272-1281. PMID: 39052257, DOI: 10.1001/jamaoncol.2024.2185.Peer-Reviewed Original ResearchAltmetricConceptsBRCA1/2 PVCancer riskPoly ADP-ribose polymeraseGenetic testingCancer genetic testingFamilial cancer riskPrimary care cliniciansEvidence of increased riskBRCA1/2-PV carriersMale carriersIncreased genetic testingRisk of breastRisk reductionCancer early detectionCancer-predisposing variantsClinical trial opportunitiesCancer therapy optionsCare cliniciansTargeted risk managementCancer screeningPV carriersHereditary cancerADP-ribose polymeraseGuideline recommendationsEarly cancer detectionHealth care utilization and behavior changes after workplace genetic testing at a large US health care system
Charnysh E, Pal S, Reader J, Uhlmann W, McCain S, Sanghavi K, Blasco D, Brandt R, Feero W, Ferber R, Giri V, Hendy K, Prince A, Lee C, Roberts J, consortium I, Crumpler N, Leader A, Mathews D, Ryan K, Spector-Bagdady K, Vogle A, Brothers K, Clayton E, Deverka P, Ellis T, Goldenberg A, Mockus S, Morton C, Rueter J, Witham B, Bessey E, Gordon E, Lee L, Roberts J, Saidi F. Health care utilization and behavior changes after workplace genetic testing at a large US health care system. Genetics In Medicine 2024, 26: 101160. PMID: 38733246, DOI: 10.1016/j.gim.2024.101160.Peer-Reviewed Original ResearchAltmetricConceptsHealth behavior changeU.S. healthcare systemHealthcare utilizationIncreased riskAssociated with health behavior changesBehavioral changesHealthcare systemPromote health behavior changeGenetic testingImprove employee healthHeart diseaseSelf-reported dataLogistic regression analysisElectronic surveyMedication changesDescriptive statisticsHealthcarePGx resultsEmployee healthHealth implicationsRegression analysisHealthPGxWorkplaceCancerPD01-01 GERMLINE PATHOGENIC VARIANTS IN PATIENTS WITH PROSTATE CANCER: RESULTS FROM THE TECHNOLOGY-ENHANCED ACCELERATION OF GERMLINE EVALUATION FOR THERAPY (TARGET) STUDY
Loeb S, Gross L, Cheng H, Rivera A, Keith S, Byrne N, Nolasco T, Giri V. PD01-01 GERMLINE PATHOGENIC VARIANTS IN PATIENTS WITH PROSTATE CANCER: RESULTS FROM THE TECHNOLOGY-ENHANCED ACCELERATION OF GERMLINE EVALUATION FOR THERAPY (TARGET) STUDY. Journal Of Urology 2024, 211: e62. DOI: 10.1097/01.ju.0001009540.33579.43.01.Peer-Reviewed Original ResearchToward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate Cancer
Vandekerkhove G, Giri V, Halabi S, McNair C, Hamade K, Bitting R, Wyatt A. Toward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate Cancer. JCO Precision Oncology 2024, 8: e2300654. PMID: 38547422, PMCID: PMC10994438, DOI: 10.1200/po.23.00654.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsClinical genomic testingGenomic testingProstate cancerTumor tissuesPoly (ADP-ribose) polymerase inhibitorsPlasma cell-free DNAHereditary cancer implicationsLow tumor fractionAdvanced prostate cancerDNA damage repair genesHealth care professionalsCell-free DNANonpathogenic variantsPatient's germlineOptimal patient careSomatic alterationsSubclonal alterationsClinical decision makingClonal hematopoiesisCare professionalsGenotyping testPoor prognosisTumor fractionPatient careCancer managementTARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing
Loeb S, Keith S, Cheng H, Leader A, Gross L, Nolasco T, Byrne N, Hartman R, Brown L, Pieczonka C, Gomella L, Kelly W, Lallas C, Handley N, Mille P, Mark J, Brown G, Chopra S, McClellan A, Wise D, Hollifield L, Giri V. TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing. JCO Precision Oncology 2024, 8: e2300552. PMID: 38452310, PMCID: PMC10939575, DOI: 10.1200/po.23.00552.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsGermline genetic testingDecisional conflictGenetic counselingProstate cancerPatient-drivenShortage of genetic counselorsKnowledge of cancer geneticsHereditary cancer riskReduce decisional conflictDecisional Conflict ScalePrimary outcome dataMixed-effects regression modelsDiverse patient populationsGenetic servicesClinical trial eligibilityGenetic counselorsGenetics educationPatient experienceCancer riskGermline testingAnalytical data setsCancer geneticsGermline evaluationConflict ScaleGenetic testingAddressing gaps in healthcare provider knowledge regarding germline testing for prostate cancer through development and testing of a virtual genetics board
Loeb S, Cheng H, Paller C, Weg E, Johnson J, Gross L, Keith S, Russo J, Hathaway F, Rivera A, Giri V. Addressing gaps in healthcare provider knowledge regarding germline testing for prostate cancer through development and testing of a virtual genetics board. Prostate Cancer And Prostatic Diseases 2024, 1-3. PMID: 38172199, DOI: 10.1038/s41391-023-00778-9.Peer-Reviewed Original ResearchCitationsP864: Employees’ views and healthcare utilization following employer-sponsored pharmacogenomic testing at a large US healthcare system
Charnysh E, Pal S, Reader J, McCain S, Hendy K, Sanghavi K, Uhlmann W, Feero W, Prince A, Brandt R, Ferber R, Giri V, Lee C, Roberts J. P864: Employees’ views and healthcare utilization following employer-sponsored pharmacogenomic testing at a large US healthcare system. Genetics In Medicine Open 2024, 2: 101778. DOI: 10.1016/j.gimo.2024.101778.Peer-Reviewed Original Research
2023
Liver Transplantation in a Woman with Mahvash Disease
Robbins J, Halegoua-DeMarzio D, Basu Mallick A, Vijayvergia N, Ganetzky R, Lavu H, Giri V, Miller J, Maley W, Shah A, DiMeglio M, Ambelil M, Yu R, Sato T, Lefler D. Liver Transplantation in a Woman with Mahvash Disease. New England Journal Of Medicine 2023, 389: 1972-1978. PMID: 37991855, DOI: 10.1056/nejmoa2303226.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPortal hypertensionLiver transplantationPancreatic hypertrophyMahvash diseasePancreatic α cell hyperplasiaAbsence of cirrhosisNoncirrhotic portal hypertensionΑ-cell hyperplasiaRare genetic disorderSerum glucagonDefinitive treatmentGlucagon levelsVascular diseaseMedical CenterHypertensionDiseaseAmmonia levelsHyperglucagonemiaGenetic disordersTransplantationHypertrophyGlucagonWomenHematemesisCirrhosis
Academic Achievements & Community Involvement
activity NCI EDRN Review Panel
Peer Review Groups and Grant Study SectionsReviewerDetails2015 - Presentactivity NCI Special Emphasis Panel
Peer Review Groups and Grant Study SectionsReviewerDetails2018 - Presentactivity American Society of Clinical Oncology
Professional OrganizationsMemberDetails2001 - Presentactivity ASCO Genetics Subcommittee
Professional OrganizationsMemberDetails2020 - Presentactivity Thomas Jefferson University Faculty Advisory Council
CommitteesMemberDetails2021 - Present
Clinical Care
Overview
Clinical Specialties
Fact Sheets
Hereditary Cancer Syndromes
Learn More on Yale MedicineProstate Cancer
Learn More on Yale Medicine
Board Certifications
Medical Oncology
- Certification Organization
- AB of Internal Medicine
- Latest Certification Date
- 2014
- Original Certification Date
- 2004
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
News
- October 28, 2024
Dr. Veda Giri on Yale Cancer Answers: A Rise in Early Onset Cancers: What Does it Mean?
- October 16, 2024Source: Washington Post
Why cancer among younger Americans is on the rise
- October 14, 2024
Preserving Hope: Fertility Care for Patients with Cancer and Hematological Disorders
- July 28, 2024Source: Brain & Body Things Podcast
Understanding Early Onset Cancer with Drs Veda Giri and Nancy Borstelmann
Get In Touch
Contacts
Yale School of Medicine
333 Cedar Street WWW214A
New Haven, CONNECTICUT 06520
United States
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.